- Global
leaders, including Amazon, Bayer, and GE Healthcare, joined the
AAIH to date to collaborate on developing novel solutions to
improve the quality of care and reduce failure rates
- The Company
recently launched a new AI program with the Mayo Foundation for
Medical Education
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it had been invited by, and accepted,
an invitation to join the Alliance for Artificial Intelligence in
Healthcare (AAIH), following BioSig’s major patent awards for its
AI-based platform that the Company recently won from the U.S.
Patent Office.
The AAIH is the global advocacy organization for the advancement
and use of artificial intelligence in healthcare to improve
patients’ lives and create more efficient, sustainable, and
accessible healthcare systems. The AAIH and its member companies
and organizations are dedicated to developing novel interventions
and product solutions to reduce failure rates and costs while
improving quality across the entire healthcare spectrum from
biomedical discovery, clinical research, medical diagnostics and
devices, and precision medicine. The initiative, which spans out of
the Alliance for Regenerative Medicine, was formally launched in
2019 with 22 founders, including Amazon WS (NASDAQ: AMZN), Bayer
(XETR: BAYN), GE Healthcare (NYSE: GE), GlaxoSmithKline (NYSE:
GSK), and the University of Pittsburg.
“Artificial intelligence excels at analyzing and
uncovering patterns in vast volumes of clinical data – a
fundamental building block in improving patient care. BioSig is a
company that is committed to providing superior technological
solutions based on precise signal information. We believe that a
joint effort between various healthcare community representatives
is a much-needed step towards solving common challenges and
accelerating the adoption of AI-powered solutions. We are excited
to join the Alliance and collaborate with its members on our shared
goals for improving the standards of patient care,’ commented
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies,
Inc.
BioSig recently launched a strategic collaboration with the Mayo
Foundation for Medical Education and Research to develop a
next-generation AI- and machine learning-powered software for the
PURE EP™ System. The Company’s platform technology provides signal
information during the cardiac ablations for the treatments of
arrhythmias or irregular heartbeats, a condition that affects over
33 million people worldwide[1]. Under the terms of the newly
launched AI initiative, the Company aims to develop novel
technological solutions to improve existing therapies by combining
the PURE EP™'s electrophysiological signals and other data
sources.
The Company has also announced major strategic
collaborations with other subject-matter experts to further the AI
and machine learning applications of the PURE EP™ System in their
collaboration for AI technical advisory services with Harvard- and
MIT-trained computer scientist and physicist, Dr. Wissner-Gross, of
Reified. In 2020, the Company co-authored an abstract with Reified,
titled ‘Computational Reconstruction of Electrocardiogram Lead
Placement,’ that presented a new method for analyzing
electrocardiograms that may ultimately help to improve the
automated classification of patient conditions.
“This is an exciting time for artificial intelligence and
machine learning applications in healthcare, and we look forward to
contributing to next-generation technological solutions in the
space,” responded Dr. Wissner-Gross.
The global market for AI in healthcare is expected to grow from
$4.9 billion in 2020 to $45.2 billion by 2026 at an estimated
compound annual growth rate (CAGR) of 44.9%. According to
Accenture, key clinical health AI applications, when combined, can
potentially create $150 billion in annual savings for the United
States healthcare economy by 2026.
About AAIHThe AAIH is a coalition of technology
developers, pharmaceutical companies, and research organizations
who have expressed the common goal of realizing the potential for
AI and machine learning in healthcare to significantly improve
quality of care, but who also recognize the need to address
substantial industry challenges. By convening stakeholders to
present a unified voice, we are working to establish responsible,
ethical, and reasonable standards for the development and
implementation of AI in healthcare. As an organization, the AAIH
brings together industry, academia, research institutions,
government NGOs, key opinion leaders, and other international
stakeholders to develop appropriate regulatory principles. By
engaging with a wide array of participants across the healthcare
spectrum, the AAIH works to actualize the promise of artificial
intelligence in medicine thereby improving patients’ lives and
creating more efficient, sustainable, and accessible healthcare
systems. Learn more on www.theaaih.org.
About BioSig TechnologiesBioSig Technologies is
a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).The Company’s first product, PURE
EP™ System is a computerized system intended for acquiring,
digitizing, amplifying, filtering, measuring and calculating,
displaying, recording and storing of electrocardiographic and
intracardiac signals for patients undergoing electrophysiology (EP)
procedures in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
1 Top 10 Things You should Know About Heart Rhythm; Scripps
Health
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024